Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMA Bispecific
- Development stage
- Unknown
- Lead developer
- HaemaLogiX
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
KMA Bispecific is a bispecific monoclonal antibody developed by HaemaLogiX. It functions as an inhibitor of kappa myeloma antigen (KMA), also known as kappa myeloma antigen inhibitors. The drug is designed to target the KMA protein, which is associated with multiple myeloma and potentially other neoplasms, immune system diseases, and cardiovascular diseases. As a bispecific antibody, it can simultaneously bind two different antigens or epitopes, enhancing its therapeutic potential in cancer immunotherapy by recruiting immune cells or interfering with disease-related signaling pathways[1][7]. Its primary indication under investigation is multiple myeloma[1].
02
Targets
CD3 (T-cell surface glycoprotein CD3)Immunoglobulin light chain
Beyond the preview
Go deeper on KMA Bispecific.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMA Bispecific.